摘要
目的探讨卵巢癌患者血清微小核糖核酸(micro RNA,miR)-128表达及与化疗效果及预后的相关性。方法选取2012年6月~2017年12月在河北大学附属医院就诊的146例卵巢癌患者为观察组,纳入患者均接受紫杉醇与卡铂药物联合治疗,另选取同期于该院进行健康体检的208例成年女性作为对照组。对比两组临床资料,采用实时荧光定量PCR(qRT-PCR)检测两组受试者血清miR-128表达水平,通过受试者工作特征曲线(ROC)确定血清miR-128表达水平的最佳截断点,对观察组患者随访三年,采用Kaplan Meier法绘制生存曲线,分析miR-128不同表达水平患者的疗效及生存情况。采用二分类COX回归分析筛选患者化疗效果不良的预测因素,并用rms程序包建立列线图预测模型,采用校准曲线评价其预测效能。结果观察组血清miR-128表达水平(0.24±0.08)明显低于健康对照组(2.35±0.17),差异有统计学意义(t=139.48,P<0.001);miR-128低表达组患者化疗后疾病控制率明显低于miR-218高表达组患者(40.95%vs 70.73%),差异具有统计学意义(χ^(2)=10.461,P<0.05);卵巢癌患者血清miRNA-128表达水平与淋巴转移、FIGO分期、分化程度和CA125异常有关(χ^(2)=28.303,33.241,48.107,22.889,均P<0.05);miRNA-128低表达、淋巴转移、FIGO分期III期以上和肿瘤分化程度低、CA125偏高是卵巢癌患者化疗效果不良的独立预测因素(OR=2.812,1.982,2.354,2.194,1.657,均P<0.05);miR-128高表达患者三年生存率明显高于低表达患者(73.17%vs 44.76%),差异有统计学意义(Log-Rankχ^(2)=9.548,P=0.002)。结论MicroRNA-128与卵巢癌的发生与发展密切相关,其表达水平对预测卵巢癌的化疗疗效和生存情况具有参考意义。
Objective To investigate the expression of serum miRNA-128 in patients with ovarian cancer and its correlation with chemotherapy effect and prognosis.Methods A total of 146 patients with ovarian cancer treated in the Affiliated Hospital of Hebei University from June 2012 to December 2017 were selected as the observation group.All the patients were treated with paclitaxel and carboplatin,and 208 adult women who underwent physical examination in the Hospital were selected as the control group.The clinical data of the two groups were compared,the serum miR-128 expression levels of the two groups of subjects were detected by real-time fluorescence quantitative PCR(qRT-PCR).The best cutoff point of serum miR-128 expression level was determined by the receiver operating characteristic curve(ROC).The patients in the observation group were followed up for three years.Kaplan Meier method was used to draw survival curves and analyze the efficacy and survival of patients with different miR-128 expression levels.Dichotomous COX regression analysis was used to screen the predictors of poor chemotherapy effect,and nomogram prediction model was established with RMS package,and its prediction efficiency was evaluated with calibration curve.Results The expression level of serum miR-128 in the observation group(0.24±0.08)was significantly lower than that of the healthy control group(2.35±0.17),and the difference was statistically significant(t=139.48,P<0.001).The complete remission and disease control rate of patients in the miR-128 low expression group after chemotherapy were significantly lower than those in the miR-218 high expression group(40.95%vs 70.73%),and the difference was statistically significant(χ^(2)=10.461,P<0.05).The expression level of miR-128 in patients with ovarian cancer was related to lymphatic metastasis,FIGO staging,degree of differentiation,and abnormal CA125(χ^(2)=28.303,33.241,48.107,22.889,all P<0.05).Low miR-128 expression,lymphatic metastasis,FIGO stage III or higher,low tumor differentiation,and
作者
李品
刘春晖
石军荣
蔡智慧
侯岩
李晶晶
齐冀
闫丽伟
LI Pin;LIU Chun-hui;SHI Jun-rong;CAI Zhi-hui;HOU Yan;LI Jing-jing;QI Ji;YAN Li-wei(Department of Gynecology,Affiliated Hospital of Hebei University,Hebei Baoding 071000,China;CT/MRI Diagnosis,Affiliated Hospital of Hebei University,Hebei Baoding 071000,China)
出处
《现代检验医学杂志》
CAS
2022年第6期104-109,共6页
Journal of Modern Laboratory Medicine
基金
保定市科技计划项目(2041ZF309)。
